High Dose Versus Low Dose Syngeneic Hepatocyte Transplantation in Pex1-G844D NMRI Mouse Model is Safe but Does Not Achieve Long Term Engraftment

Tanguy Demaret, Jonathan Evraerts, Joachim Ravau, Martin Roumain, Giulio G. Muccioli, Mustapha Najimi and Etienne M. Sokal

Abstract: Genetic alterations in PEX genes lead to peroxisome biogenesis disorder. In humans, they are associated with Zellweger spectrum disorders (ZSD). No validated treatment has been shown to modify the dismal natural history of ZSD. Liver transplantation (LT) improved clinical and biochemical outcomes in mild ZSD patients. Hepatocyte transplantation (HT), developed to overcome LT limitations, was performed in a mild ZSD 4-year-old child with encouraging short-term results. Here, we evaluated low dose (12.5 million hepatocytes/kg) and high dose (50 million hepatocytes/kg) syngeneic male HT via intrasplenic infusion in the Pex1-G844D NMRI mouse model which recapitulates a mild ZSD phenotype. HT was feasible and safe in growth retarded ZSD mice. Clinical (weight and food intake) and biochemical parameters (very long-chain fatty acids, abnormal bile acids, etc.) were in accordance with ZSD phenotype but they were not robustly modified by HT. As expected, one third of the infused cells were detected in the liver 24 h post-HT. No liver nor spleen microchimerism was detected after 7, 14 and 30 days. Future optimizations are required to improve hepatocyte engraftment in Pex1-G844D NMRI mouse liver. The mouse model exhibited the robustness required for ZSD liver-targeted therapies evaluation.

Keywords: peroxisome biogenesis disorder; Zellweger spectrum disorder; oxysterols; mouse model; PEX1 p.Gly844Asp; PEX1 c.2528G>A

1. Introduction

Zellweger spectrum disorders (ZSD) are caused by genetic alterations in PEX genes encoding peroxins [1]. Peroxin deficiency lead to peroxisome biogenesis disorder and metabolic imbalance [2]. Metabolites catabolized into peroxisomes (i.e., branched-chain fatty acids (BCFA: phytanic and pristanic acids), very long-chain fatty acids (VLCFA: C\textsubscript{22}, C\textsubscript{24}, C\textsubscript{26}), C\textsubscript{27} bile acids (BA) precursors, etc.) accumulate into plasma and tissues, and compounds synthetized in the peroxisomes are deficient (i.e., plasmalogens, C\textsubscript{24} BA, etc.) [3]. Most mild ZSD patients survive into childhood, however no validated treatment is able to impact their progressive hepatic dysfunction and developmental delay [4]. In this context, we and others have obtained proof-of-principle that liver-targeted therapies such as living donor liver transplantation (LT) and hepatocyte transplantation (HT) can modify disease progression in mild ZSD patients [5–8].

Because organ shortage is a major hurdle to pediatric LT, several techniques have been developed to increase organ availability (living donor LT, split-liver, etc.) [9–11]. Yet, parenchymal function is often preserved in liver-based metabolic diseases making it...
difficult for these patients to progress on LT waiting list [12]. Hepatocyte transplantation (HT) was developed to overcome LT limitations (i.e., heaviness, cost, organ availability, etc.). HT consists in isolating hepatocytes from liver not suitable for LT and infusing them to a recipient with or without cryopreservation [13]. First pediatric HT procedure performed in Europe was for a four-year-old child affected by mild ZSD [8]. It led to encouraging biochemical results.

With an estimated incidence rate close to 1/100,000, ZSD meet rare disease criteria [14–16]. Since robust placebo-controlled clinical trials are out of the scope in these diseases, treatments are mainly evaluated in animal models which allow rigorous controlled conditions [17]. The Pex1-G844D NMRI mouse model we recently developed displays biochemical and hepatic alterations affecting mild ZSD patients [18]. Interestingly, its easy breeding and robustness make it suitable for preclinical studies and intervention like HT.

In order to strengthen liver-directed therapies in mild ZSD therapeutic approaches, we evaluated two HT protocols in Pex1-G844D NMRI mouse model. We followed clinical and biochemical parameters along with liver hepatocyte engraftment to monitor HT impacts on mild ZSD phenotype.

2. Materials and Methods

2.1. Mice Care, Breeding and Genotyping

Heterozygous Pex1-G844D NMRI mice from in-house colony were bred in a specific-pathogen-free environment, and in individually ventilated cages with 12 h light/12 h dark cycle [18]. Wild-type and heterozygous mice exhibited no phenotype difference and were used as control mice. Mice had unrestricted access to food (Carfil, Oud-Turnhout, Belgium, Mice Breeding diet) and water, and were genotyped as described earlier [18]. All animal experiments were carried out in accordance with the EU Directive 2010/63/EU for animal experiments and approved by the Ethical Committee for Animal Experimentation at the Health Science Sector, UCLouvain, Brussels, Belgium (2017/UCL/MD/006).

2.2. Hepatocyte Transplantation

Male mouse hepatocytes were isolated from control littermate by collagenase P (Roche, Indianapolis, IN, USA, 11213873001) as we previously described [19]. Cells were suspended at 1.25 or 5 million hepatocytes/mL in N-acetylcysteine 4% (NAC, Lysomucyl, Zambon, Bruxelles, Belgium) in phosphate buffered saline (PBS, Lonza, Walkersville, MD, USA, 15-512F). NAC was shown to inhibit de procoagulant activity of isolated hepatocytes [20]. Two HT protocols were evaluated based on 12.5 or 50 million cells/kg (10 µL/g of body weight), further referred as low dose HT and high dose HT, respectively. They were defined to deliver a number of hepatocytes representing ~0.1 and ~0.5% of the recipient liver, respectively. In the low dose protocol, we infused a relatively limited number of hepatocytes to minimally trigger the mechanisms responsible for their clearance (vide Discussion). Younger mice (4 weeks) were transplanted in order to take benefit from the proliferation signals present in the growing liver. The longer follow-up (4 weeks) post-HT was designed to allow the proliferation of the infused hepatocytes. In the high dose protocol, older larger mice (6 weeks) received a higher (absolute and relative) number of hepatocytes to evaluate the effect of engrafted and circulating hepatocytes. This was combined with a shorter follow-up (2 weeks) to prevent the consequences of hepatocyte loss. HT was performed in the morning based on a modified protocol from [21]. Briefly, under isoflurane anesthesia, freshly isolated hepatocytes were infused by intrasplenic injection through 25 G needle at 50 µL/minute with a syringe press (CMA 400 microdialysis, Kista, Sweden) (Figure 1A,B). Control mice received 100 µL PBS-NAC. All mice received subcutaneous 20 mL/kg warmed NaCl 0.9% (Mini-Plasco NaCl 0.9%, B. Braun, Diegem, Belgium) along with 0.1 mg/kg buprenorphine (Temgesic, Schering-Plough, Kenilworth, NJ, USA) once before the procedure and then twice a day for 2 days. Mice groups and follow-up are presented (Table 1, Figure 1C). Two ZSD mice infused with high dose HT were sacrificed.
earlier to evaluate microchimerism longitudinally (Figure 1C). These mice were excluded from HT outcomes analysis.

Figure 1. Mouse hepatocyte transplantation (HT) setup and HT protocols description. (A) Mouse in right lateral decubitus with intra-splenic 25 G needle insertion. Note the discolored spleen area inside the dotted line confirming the correct intra-splenic infusion flushing erythrocytes. (B) Device setup used for HT: syringe press on the right, heating pad (green) and anesthesia tunnel delivering isoflurane mixed with oxygen and collecting exhaled gases. (C) Schematic description of the two HT protocols including fasting tests, sacrifices for microchimerism evaluation and samples collection at the end of the study. (D) Macroscopic liver evaluation 24 h after high dose HT highlighting large necrosis areas in right and left median lobes. Left lateral lobe displayed smaller necrosis areas (white arrows). Inserts show magnification of the boxed areas.

Table 1. Hepatocyte Transplantation Protocol Description.

| HT Protocol | Dose          | HT (Age) | Sacrifice (Age) | Control Mice + PBS-NAC | ZSD Mice+ HT | ZSD Mice + PBS-NAC |
|-------------|---------------|----------|----------------|------------------------|--------------|---------------------|
| Low dose HT | 12.5 million/kg | 4 weeks  | 8 weeks        | 6                      | 3            | 2                   |
| High dose HT| 50 million/kg  | 6 weeks  | 8 weeks        | 6                      | 10 *         | 6                   |

*: Mice were sacrificed after 1 day (n = 1) and 7 days (n = 1) for longitudinal microchimerism evaluation, and were excluded from HT outcomes analysis. HT: hepatocyte transplantation, PBS: phosphate buffered saline, NAC: N-acetylcysteine.

2.3. Clinical Evaluation and Glycemia

Food and mouse weight were measured once a week. Morning glycemia was measured on tail vein blood droplet using glucometer (FreeStyle Precision Neo, Abbott, Princeton, NJ, USA). Mice were fasted 6 h in a clean cage with access to water before glycemia quantification to evaluate their glycemic response to fast (Figure 1C).

2.4. Blood and Liver Collection

Four or 2 weeks post-HT (Table 1), mice were anesthetized by intraperitoneal injection with a solution containing ketamine and xylazine at final concentration of 100 mg/kg and
10 mg/kg, respectively. Plasma and liver lobes were collected as described previously [18]. Briefly, plasma was aliquoted and snap frozen in liquid nitrogen. Left lateral lobe was fixed in formaldehyde 4% (VWR, Lille, France, 11699408) overnight and embedded in paraffin for histological analysis. Left medial lobe (LML) was snap frozen in liquid nitrogen and stored at −80 °C for biochemical and microchimerism analysis.

2.5. Peroxisomal Markers Quantification

BCFA, VLCFA, oxysterols, BA and pipecolic acid were quantified as described earlier [18].

2.6. Histological Analyses

Formalin-fixed paraffin-embedded left lateral liver lobes were cut into 5 µm thick wide sections and processed for hematoxylin and eosin (HE), Periodic-acid Schiff (PAS) and Sirius red (SR) staining. Slides were processed for digitalization and quantification as previously described [18].

2.7. Microchimerism Evaluation

Theoretical microchimerism at infusion was estimated by dividing infused hepatocytes number by NMRI mouse hepatocellularity equivalent to (mean ± standard deviation (SD)) 109 ± 8 million hepatocytes/liver g individually adjusted for current liver weight extrapolated from relative liver weight at sacrifice. NMRI mouse hepatocellularity was calculated as described elsewhere [22], based on protein quantification of 9 NMRI mice livers and 2 NMRI mice hepatocyte suspensions. Mice LML and spleen were screened for microchimerism (male hepatocytes in female organ) based on predesigned droplet digital polymerase chain reaction (ddPCR) Sry (Mm.PT.58.28492124.g, Integrated DNA Technologies, Louvain, Belgium) and Rpp30 (qMmuCEP0054985, Bio-Rad, Hercules, CA, USA) assays performed in multiplex on genomic DNA as described here [23]. Sry and Rpp30 are located on chromosomes Y and 19, respectively. Sry/Rpp30 copy number ratio is expected to be equal to 0.5 and 0 in male and female, respectively. Male microchimerism in female is equivalent to Sry/Rpp30 copy number ratio multiplied by two because Sry is present in one copy (on Y chromosome) for each two Rpp30 copies (on chromosomes 19).

2.8. General Statistical Analysis and Artwork

Kruskal-Wallis test with Dunns post-test with 95% confidence intervals were performed using GraphPad Prism v. 5.02 for Windows (GraphPad Software, San Diego, CA, USA). p-values < 0.05 were considered significant. When considered significant, Dunns post-test was reported on graph. Publisher (Office 365, Microsoft, Redmond, WA, USA) was used to draw figures.

3. Results

3.1. Hepatocyte Transplantation Was Safe and Well Tolerated by ZSD Mice

In the next hours following HT, mice cleaned the surgical wound as detected by decreased povidone-iodine staining on post-operative day (POD) 1. To avoid suture traction, food kibbles were disposed on the litter during 24 h and mice started to eat them during POD1. Macroscopic liver evaluation at POD1 showed large necrosis area (Figure 1D) without clinical impact. During the post-HT period, none of the mice lost more than 5% body weight and none of the mice died (Figures 2A and 3A). Food intake was not modified by HT (see below).
Figure 2. Low dose hepatocyte transplantation (HT) did not impact ZSD mice disease markers. (A) Relative body weight change at post-operative day (POD) 1, (B) relative weight gain at final follow-up, (C) normalized daily energy intake, (D) liver branched-chain and very long-chain fatty acids levels and ratio on C22, (E) plasma and liver oxysterols 7-hydroxycholesterol (7-OHC) and (F) 7α-hydroxycholestenone (7α-OHCnone) levels, (G) plasma and liver total C27 bile acids (BA) precursors levels, (H) plasma, liver and plasma-liver ratio of total conjugated C24 BA levels, (I) fed glycemia, (J) relative fasting glycemia drop (both fasting tests gave similar results and were merged on the graph, an outlier control mice was excluded from both tests), (K) relative liver Periodic-acid Schiff (PAS)-positive stained area (proxy for glycogen content), (L) relative liver Sirius red-positive stained area (proxy for collagen content) and (M) relative liver weight at sacrifice in control \(n = 6\), Zellweger spectrum disorder (ZSD) mice infused with low dose HT \(n = 3\) and ZSD mice sham operated \(n = 2\). HT outcome measures highlighted disease phenotype in ZSD mice but failed to detect low dose HT impact in treated mice. Kruskal-Wallis test, \(n (\text{Control – ZSD + HT – ZSD}) = 6 – 3 – 2\) (except for D: \(n = 3 – 3 – 2\) and J: \(n = 10 – 6 – 4\)), median ± interquartile range, *: \(p\)-value < 0.05, n.s.: not significant.
Figure 3. High dose hepatocyte transplantation (HT) was safe but failed to convincingly modify peroxisomal markers in ZSD mice. Relative body weight change at (A) post-operative day (POD) 7 or (B) sacrifice, (C) normalized daily energy intake, (D) plasma pipecolic acid levels, (E) fed glycemia, (F) relative fasting glycemia drop, (G) relative liver Periodic-acid Schiff (PAS)-positive stained area (proxy for glycogen content) and (H) relative liver weight in control (n = 6), Zellweger spectrum disorder (ZSD) mice treated with high dose HT (n = 8) and ZSD mice sham operated (n = 6). High dose HT protocol confirmed ZSD phenotype in affected mice and corrected fasting glycemia drop in ZSD mice but this was not correlated to increased liver PAS-positive stained area. Kruskal-Wallis test, n (Control – ZSD + HT – ZSD) = 6 – 8 – 6, median ± interquartile range, *: p-value < 0.05, **: p-value < 0.01, ***: p-value < 0.0001, n.s.: not significant.

3.2. Growth and Normalized Daily Energy Intake Were Not Affected by HT in ZSD Mice

ZSD mice exhibit growth retardation despite higher normalized daily energy intake [18]. These anomalies were confirmed in this study and were not modified by low nor high dose HT (Figure 2B,C and Figure 3B,C).

3.3. HT Did Not Modify Plasma nor Liver Peroxisomal Marker Anomalies in ZSD Mice

ZSD mice show liver and plasma peroxisomal marker alterations classically found in ZSD patients [18]. In this study, liver BCFA were not detected in control mice and they did not seem affected by low dose HT in ZSD mice (Figure 2D). Liver VLCFA levels quantification did not highlighted significant accumulation in ZSD mice because of low sample size (Figure 2D). Plasma and liver oxysterols and BA levels were in accordance with our previous report and were not modified by low dose HT (Figure 2E–H). ZSD mice cholestasis was confirmed by total conjugated C24 BA plasma-liver ratio elevation, as previously reported [18], and it was not influenced by HT (Figure 2H).

Based on our experience of dramatic plasma pipecolic acid levels decrease shortly after LT and HT in ZSD patients [7,8], we chose to focus on this biochemical marker for the high dose HT protocol. As previously reported in our ZSD mouse model [18], plasma pipecolic acid levels were increased in ZSD mice. Unfortunately, high dose HT did not modify this parameter (Figure 3D).

3.4. Fasting Glycemia in ZSD Mice Was Improved after High Dose HT but this Was Not Correlated to Liver Glycogen Content

ZSD mice present glycemic alterations related to liver glycogen metabolism anomalies [18]. Fed glycemia was not significantly different between control and ZSD mice (Figures 2I and 3E). Fasting glycemia was significantly lower in ZSD mice and this was rescued by high dose HT (Figures 2 and 3F). Unfortunately, this was not correlated to liver PAS-positive stained area (a proxy for liver glycogen content [18]) which remained strongly lower in ZSD mice liver compared to control (Figures 2K and 3G).
3.5. HT Did Not Reverse Relative Hepatomegaly in ZSD Mice

ZSD mice liver present a slight elevation in collagen deposition as measured by SR staining. This was not statistically evident in low dose HT ZSD mice partly because of the small sample size (Figure 2L). Another striking ZSD mice feature is their relative hepatomegaly [18]. This was confirmed in both HT protocols, but they failed to modify this hallmark of the disease (Figures 2M and 3H).

3.6. Post-HT, Liver Histological Analysis Highlighted Spontaneously Resolving Necrosis and Confirmed ZSD Liver Pathology Hallmarks Compared to Controls

To decipher post-HT engraftment, liver pathology analysis was performed on liver sections. Since the infused hepatocytes were isolated from a control littermate (i.e., a syngeneic donor), no specific histological marker could be used to localize the transplanted cells and engraftment was further measured by ddPCR (vide infra). As expected from previous report [24] and from the POD1 macroscopic liver evaluation (Figure 1D), POD1 liver HE staining in ZSD + HT mice showed necrosis areas with inflammatory cells infiltrate, sparing the central vein (CV) (Figure 4A). Liver necrosis resolved before POD7 and liver tissue architecture was preserved post-HT. ZSD liver displayed classical canalicular proliferation and progressive hepatocyte hypertrophy from portal tract (PT) to CV compared to wild-type control mice [18] (Figure 4B,C).

**Figure 4.** Liver histological analysis in Zellweger spectrum disorder (ZSD) mice confirmed ZSD liver disease hallmarks and uncovered spontaneously resolving focal liver necrosis following hepatocyte transplantation (HT). (A) Post-operative day (POD) 1 mice liver exhibited necrosis areas with inflammatory cells infiltrate (dotted lines) sparing the central vein (CV), along with ballooning degeneration of hepatocytes (arrows). POD7 and POD14 and (B) control (PBS-NAC) ZSD livers showed canalicular proliferation in portal tracts (PT) and progressive hepatocyte hypertrophy from portal tract (PT) to CV, as previously reported [18]. Necrosis was not detected at POD7 and POD14, nor in ZSD control livers, nor in (C) wild-type (WT) control livers. PBS-NAC: N-acetylcysteine in phosphate buffered saline. Scale bar: 100 µm.
3.7. Male Liver Microchimerism Was Detected in Female ZSD Mice 24 h Post-HT and Was Lost during Follow-up

Theoretical liver microchimerism at infusion was (mean ± SD) 0.110 ± 0.003% (n = 3) and 0.461 ± 0.038% (n = 10) for low dose and high dose HT, respectively. Sry/Rpp30 copy number ratio was measured by ddPCR on more than 35,000 droplets for each sample (Table 2). No liver microchimerism could be detected on low dose HT protocol samples (n = 2 females). At high dose HT POD1, liver microchimerism was 0.15%, which is equivalent to one third of the theoretical liver microchimerism at infusion (n = 1 female). After POD1, no significant liver microchimerism was detected (n = 5 females). For both protocols, no significant spleen microchimerism was detected by ddPCR (data not shown).

Table 2. Microchimerism evaluation on mice liver in low dose and high dose HT protocols.

| Sample                  | Total Droplet Count | Mean Sry Concentration (Copy Number/µL) | Mean Rpp30 Concentration (Copy Number/µL) | Mean Sry/Rpp30 Ratio | Calculated Microchimerism |
|-------------------------|---------------------|----------------------------------------|-------------------------------------------|----------------------|---------------------------|
| Male hepatocytes        | 52,789              | 464.750                                | 896.750                                    | 0.518467             | n.a.                      |
| No gDNA control         | 55,916              | 0                                      | 0                                         | n.a.                 | n.a.                      |
| Male + PBS-NAC          | 36,195              | 507.333                                | 1020.000                                   | 0.499494             | n.a.                      |
| Female + PBS-NAC        | 48,151              | 0                                      | 945.667                                    | 0                    | n.a.                      |
| Female + HT             | 48,029              | 0                                      | 956.667                                    | 0                    | 0%                        |
| Female + HT (POD1)      | 38,277              | 0                                      | 1305.667                                   | 0                    | 0%                        |
| Male + PBS-NAC          | 51,464              | 513.500                                | 1004.750                                   | 0.511389             | n.a.                      |
| Female + PBS-NAC        | 52,453              | 0                                      | 1100.000                                   | 0                    | n.a.                      |
| Female + HT (POD1)      | 55,802              | 0.700                                  | 944.250                                    | 0.000748             | 0.150%                    |
| Female + HT (POD7)      | 54,368              | 0                                      | 913.500                                    | 0                    | 0%                        |
| Female + HT             | 57,503              | 0                                      | 1002.250                                   | 0                    | 0%                        |
| Female + HT             | 59,883              | 0.020 *                                | 1043.250                                   | 0.000018             | 0.004%                    |
| Female + HT (POD1)      | 55,444              | 0                                      | 939.500                                    | 0                    | 0%                        |
| Female + HT             | 58,628              | 0                                      | 991.500                                    | 0                    | 0%                        |

Microchimerism was evaluated by droplet digital polymerase chain reaction (ddPCR) on genomic DNA (gDNA) extracted from female mouse liver and adequate controls (male hepatocytes, male liver and female liver sham infused). ddPCR was used to detect gDNA Sry (Y chromosome) and Rpp30 (chromosome 19) copies in female mice infused with male mouse hepatocytes. *: based on one positive droplet. HT: hepatocyte transplantation, n.a.: not applicable, PBS-NAC: phosphate buffered saline and N-acetylcysteine (=sham), POD: post-operative day.

4. Discussion

To date, no validated treatment has been shown to modify the natural history of ZSD. Here, we report the evaluation of low dose versus high dose HT as therapeutic approach in a mild ZSD mouse model. We confirmed robustness and ZSD phenotype in Pex1-G844D homozygous mice. Both HT doses were safe despite the growth retardation affecting the ZSD mice. However, no long term hepatocyte engraftment could be detected. In consequence, no clinically relevant therapeutic effect was convincingly evidenced.

The first HT for liver-based metabolic disease were performed in animal models and patients devoid of liver injury phenotype [25–27]. Since then, successful HT protocols were reported in patients affected by chronic liver disease [28]. ZSD mouse models and patients exhibit chronic liver disease [18,29,30], and our team reported the safety of HT in a 4-year-old ZSD patient [8]. Our ZSD mouse model express a severe disease phenotype with growth retardation along with chronic liver injury and fibrosis [18,29]. Yet, this phenotype did not impede the feasibility of HT. This supports the safety of HT in ZSD, a disease associated with chronic liver disease.

Two third of the infused hepatocytes were lost 24 h post-HT, as published in rat and mouse models of HT [31,32]. In ZSD mice, toxic peroxisomal metabolites could potentially alter hepatocytes viability in the circulation before they reach liver sinusoids [33]. In addition, granulocytes, mononuclear cells [34] and Kupfer cells [35] seem to be a major player in exogenous cell clearance. Altering Kupfer cell phagocytic properties improves engraftment in HT rat model [35]. Moreover, HT triggers the instant blood-mediated inflammatory reac-
tion (IBMIR), a process implicating the coagulation cascade which might explain the loss of transplanted hepatocytes [36]. In our model, NAC was used to prevent the procoagulant activity of the hepatocytes [20]. NAC might be insufficient and optimized anti-coagulation protocols should be evaluated for HT as it has been developed for liver-derived mesenchymal cells cell-based therapies [24,37]. Finally, the size of mouse hepatocytes and sinusoids could account for the lower cell engraftment observed compared HT in rat models [38,39]. In a previous study, syngeneic male HT in female mice lead to 0.13–0.25% microchimerism 3–7 days after HT, but no longitudinal data are reported and HT protocol is lacking (i.e., mouse background, drug used to improve engraftment, etc.) [31].

A 4-year-old mild ZSD patient received 2 billion hepatocytes ($10^8$ cells/kg of body weight, 2.5% theoretical microchimerism [27]) during a total of 5 days [8]. Male in female microchimerism measured on liver biopsy performed on the day of the last infusion reported 0.1–0.25% male cells [31]. In this child, hepatocyte loss during HT was equal to 90–95% as measured on last day of infusion. No long term hepatocyte engraftment was measured but biochemical parameters improved suggesting cell persistence [8]. Yet, after short term effect resulting probably from circulating cells (up to day 5) spontaneous trend to biochemical normalization cannot be excluded as it has been reported in some mild ZSD patients [40]. Compared to LT, HT biochemical impact is reduced in ZSD patients [7].

Poor hepatocyte engraftment in ZSD mice could be explained by the absence of selective advantage of the infused wild-type hepatocytes over ZSD hepatocytes. Hepatocyte proliferation was reported in ZSD mice liver but no necrosis was detected [18]. Absence of space for hepatocyte engraftment could be a major factor impairing HT in ZSD mouse liver. Moreover engraftment could be partly impaired in ZSD mice liver due to Cxcl12 and Hgf downregulation (GSE145524), chemokines implicated in mesenchymal stromal cells recruitment and hepatocyte proliferation, respectively [41]. Several strategies have been developed to improve hepatocyte engraftment such as hepatotoxic drugs [35], preparative hepatic irradiation [42] combined or not with partial hepatectomy [25] and (repeated) reversible portal vein embolization [43]. The vast majority were evaluated in rat models of HT. In mice, uPA$^{+/+}$-SCID mouse model combines liver insult leading to regenerative stimulus and immunosuppression for xenogenic liver cell therapy. Combining uPA$^{+/+}$-SCID background to Pex1-G844D NMRI mouse was not attempted because it would potentially modify the robustness of the model [44]. Globally, only a fraction of these approaches are translatable into clinical practice and most of them are not devoid of risks [45].

Our study strengthened the ZSD phenotype of Pex1-G844D NMRI mouse model and demonstrated its suitability for therapeutic interventions like liver cell therapy in young light ZSD mice. Small sample size in low dose HT protocol limited the statistical significance of the results. Nevertheless, high dose HT protocol allowed us to conclude that hepatocyte engraftment was a barrier to therapeutic efficacy. In the future, techniques to improve liver cell engraftment (see above) or liver Pex1 gene therapy could be evaluated in this mild ZSD mouse model to restore liver peroxisome biogenesis. Proof of concept was already evaluated by HT and LT in mild ZSD patients [7,8].

5. Conclusions

HT in Pex1-G844D NMRI mice was safe and confirmed the robustness and the ZSD phenotype. Both low dose and high dose HT failed to achieve long term hepatocyte engraftment. In consequence, no impact on disease markers was evidenced.

Author Contributions: Conceptualization, T.D., M.N. and E.M.S.; methodology, T.D., M.R., G.G.M., M.N. and E.M.S.; validation, T.D. and M.R.; formal analysis, T.D.; investigation, T.D., J.E., J.R. and M.R.; resources, G.G.M. and E.M.S.; writing—original draft preparation, T.D. and M.R.; writing—review and editing, T.D., J.E., J.R., M.R., G.G.M., M.N. and E.M.S.; visualization, T.D.; supervision, G.G.M., M.N., E.M.S.; funding acquisition, T.D., G.G.M. and E.M.S. All authors have read and agreed to the published version of the manuscript.

Funding: Tanguy Demaret is a FRIA Grant Holder of the Fonds de la Recherche Scientifique-FNRS.
Institutional Review Board Statement: All animal experiments were carried out in accordance with the EU Directive 2010/63/EU for animal experiments and approved by the Ethical Committee for Animal Experimentation at the Health Science Sector, UCLouvain, Brussels, Belgium (2017/UCL/MD/006).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The authors thank Michele De Beukelaer, Tamah Abderrahman and Philippe Debeuyne for excellent technical assistance. P’ Philippe Lysy provided glucometer & strips.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Steinberg, S.J.; Chen, L.; Wei, L.; Moser, A.; Moser, H.; Cutting, G.; Braverman, N. The PEX Gene Screen: Molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum. *Mol. Genet. Metab.* 2004, 83, 252–263. [CrossRef] [PubMed]
2. Portsteffen, H.; Beyer, A.; Becker, E.; Epplen, C.; Pawlak, A.; Kunau, W.H.; Dodt, G. Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders. *Nat. Genet.* 1997, 17, 449–452. [CrossRef] [PubMed]
3. Falkenberg, K.D.; Braverman, N.E.; Moser, A.B.; Steinberg, S.J.; Klouwer, F.C.; Schlüter, A.; Ruiz, M.; Pujol, A.; Engvall, M.; Naess, K.; et al. Allelic Expression Imbalance Promoting a Mutant PEX6 Allele Causes Zellweger Spectrum Disorder. *Am. J. Hum. Genet.* 2017, 101, 965–976. [CrossRef] [PubMed]
4. Klouwer, F.C.C.; Berendse, K.; Ferdinandusse, S.; Wanders, R.J.A.; Engelen, M.; Poll-The, B.T. Zellweger syndrome spectrum disorders: Clinical overview and management approach. *Orphanet J. Rare Dis.* 2015, 10, 1–11. [CrossRef] [PubMed]
5. Van Maldergem, L.; Moser, A.B.; Vincent, M.-F.; Roland, D.; Reding, R.; Otte, J.-B.; Wanders, R.; Sokal, E. Orthotopic liver transplantation from a living-related donor in an infant with a peroxisome biogenesis defect of the infantile Refsum disease type. *J. Inherit. Metab. Dis.* 2005, 28, 593–600. [CrossRef] [PubMed]
6. Matsunami, M.; Shimozawa, N.; Fukuda, A.; Kumagai, T.; Kubota, M.; Chong, P.F.; Kasahara, M. Living-Donor Liver Transplantation from a Heterozygous Parent for Infantile Refsum Disease. *Pediatrics* 2016, 137, e20153102. [CrossRef]
7. Demaret, T.; Varma, S.; Stephene, X.; Smets, F.; Scheers, I.I.; Wanders, R.; Van Maldergem, L.; Reding, R.; Sokal, E. Living-donor liver transplantation for mild Zellweger spectrum disorder: Up to 17 years follow-up. *Pediatr. Transplant.* 2018, 22, e13112. [CrossRef]
8. Sokal, E.M.; Smets, F.; Bourgois, A.; Van Maldergem, L.; Buts, J.-P.; Reding, R.; Otte, J.B.; Evrard, V.; Truong, D.Q.; Vincent, M.-F.; et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: Technique, safety, and metabolic follow-up. *Transplantation* 2003, 76, 735–738. [CrossRef]
9. Otte, J.-B.; Goyet, J.D.V.; Reding, R.; Van Obbergh, L.; Veyckemans, F.; Carlier, M.; De Kock, M.; De Cleey, S.C.; Clapuyt, P.; Sokal, E.; et al. Pediatric liver transplantation: From the full-size liver graft to split, split, and living related liver transplantation. *Pediatri. Surg. Int.* 1998, 13, 308–318. [CrossRef]
10. Gurevich, M.; Guy-Viterbo, V.; Janssen, M.; Stephene, X.; Smets, F.; Sokal, E.; Lefebvre, C.; Balligand, J.L.; Pirotte, T.; Veyckemans, F.; et al. Living Donor Liver Transplantation in Children: Surgical and Immunological Results in 250 Recipients at Universite Catholique de Louvain. *Ann. Surg.* 2015, 262, 1141–1149. [CrossRef]
11. Otte, J.-B. Pediatric liver transplantation: Personal perspectives on historical achievements and future challenges. *Liver Transplant.* 2016, 22, 1284–1294. [CrossRef] [PubMed]
12. Khan, Z.; Strom, S.C. Hepatocyte Transplantation in Special Populations: Clinical Use in Children. In *Methods in Molecular Biology*; Springer Science and Business Media LLC: Berlin/Heidelberg, Germany, 2016; Volume 1506, pp. 3–16.
13. Coppin, L.; Sokal, E.; Stephene, X. Hepatocyte Transplantation in Children. *Adv. Struct. Saf. Stud.* 2016, 1506, 295–315.
14. Vasiljevic, E.; Ye, Z.; Pavelc, D.M.; Darst, B.F.; Engelmann, C.D.; Baker, M.W. Carrier frequency estimation of Zellweger spectrum disorder using ExAC database and bioinformatics tools. *Genet. Med.* 2019, 21, 1969–1976. [CrossRef]
15. Braverman, N.E.; Raymond, G.V.; Rizzo, W.B.; Moser, A.B.; Wilkinson, M.E.; Stone, E.M.; Steinberg, S.J.; Wangler, M.F.; Rush, E.T.; Hacia, J.G.; et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. *Mol. Genet. Metab.* 2016, 117, 313–321. [CrossRef] [PubMed]
16. Richter, T.; NeslÃ¡er-Parr, S.; Babela, R.; Khan, Z.M.; Tesoro, T.; Molsen, E.; Hughes, D.A. Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. *Value Health* 2015, 18, 906–914. [CrossRef]
17. Moro, C.A.; Hanna-Rose, W. Animal Model Contributions to Congenital Metabolic Disease. *Adv. Exp. Med. Biol.* 2020, 1236, 225–244. [CrossRef]
18. Demaret, T.; Roumain, M.; Ambrose, J.; Evraerts, J.; Ravau, J.; Bouzin, C.; Bearzatto, B.; Gala, J.-L.; Stepman, H.; Marie, S.; et al. Longitudinal study of Pex1-G844D NMRI mouse model: A robust pre-clinical model for mild Zellweger spectrum disorder. *Biochim. et Biophys. Acta (BBA) Mol. Basis Dis.* 2020, 1866, 165900. [CrossRef]
19. Stéphenne, X.; Najimi, M.; Ngoc, D.K.; Smets, F.; Hue, L.; Guigas, B.; Sokal, E. Cryopreservation of Human Hepatocytes Alters the Mitochondrial Respiratory Chain Complex 1. *Cell Transplant.* 2007, 16, 409–419. [CrossRef]

20. Stéphenne, X.; Vosters, O.; Najimi, M.; Beuneu, C.; Ngoc, D.K.; Wijns, W.; Goldman, M.; Sokal, E.M. Tissue factor-dependent procoagulant activity of isolated human hepatocytes: Relevance to liver cell transplantation. *Liver Transplant.* 2007, 13, 599–606. [CrossRef]

21. Angarita, S.A.; Truong, B.; Khoja, S.; Nitzahn, M.; Rajbhandari, A.K.; Zhuravka, I.; Duarte, S.; Lin, M.G.; Lam, A.K.; Cederbaum, S.D.; et al. Human hepatocyte transplantation corrects the inherited metabolic liver disorder arginase deficiency in mice. *Mol. Genet. Metab.* 2018, 124, 114–123. [CrossRef]

22. Sohlenius-Sternbeck, A.-K. Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. *Toxicol. Vitro.* 2006, 20, 1582–1586. [CrossRef] [PubMed]

23. Lombard, C.; Fabre, A.; Ambroise, J.; Ravaud, J.; André, F.; Jazouli, N.; Najimi, M.; Stéphenne, X.; Smets, F.; Vaerman, J.-L.; et al. Detection of Human Microchimerism following Allogeneic Cell Transplantation Using Droplet Digital PCR. *Stem Cells Int.* 2019, 2019, 11. [CrossRef] [PubMed]

24. Coppin, L.; Najimi, M.; Bodart, J.; Rouchon, M.-S.; Van Der Smissen, P.; Eeckhoudt, S.; Dahlqvist, G.; Castanares-Zapatero, D.; Komuta, M.; Brouns, S.L.N.; et al. Clinical Protocol to Prevent from Thrombogenic Effect of Liver-Derived Mesenchymal Cells for Cell-Based Therapies. *Cells* 2019, 8, 846. [CrossRef] [PubMed]

25. Guha, C.; Parashar, B.; Deb, N.J.; Garg, M.; Gorla, G.R.; Singh, A.; Roy-Chowdhury, N.; Vikram, B.; Roy-Chowdhury, J. Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection. *Hepatology* 2002, 36, 354–362. [CrossRef]

26. Matas, A.J.; Sutherland, D.E.; Steffes, M.W.; Mauer, S.M.; Sowe, A.; Simmons, R.L.; Najarian, J.S. Hepatocellular transplantation for metabolic deficiencies: Decrease of plasma bilirubin in Gunn rats. *Science* 1976, 192, 892–894. [CrossRef]

27. Fox, I.J.; Chowdhury, J.R.; Kaufman, S.S.; Goertzen, T.C.; Chowdhury, N.R.; Warkentin, P.I.; Dorko, K.; Sauter, B.V.; Strom, S.C. Treatment of the Crigler–Najjar Syndrome Type I with Hepatocyte Transplantation. *N. Engl. J. Med.* 1998, 338, 1422–1427. [CrossRef]

28. Hansel, M.C.; Gramignoli, R.; Skvorak, K.J.; Dorko, K.; Marongiu, F.; Blake, W.; Davila, J.; Strom, S.C. The History and Use of Human Hepatocytes for the Treatment of Liver Diseases: The First 100 Patients. *Curr. Protoc. Toxicol.* 2014, 62, 12–14. [CrossRef]

29. Berendse, K.; Boek, M.; Gijbels, M.; Van Der Wel, N.N.; Klouwer, F.C.; Bergh-Weerman, M.A.V.D.; Shinde, A.B.; Ofman, R.; Poll-The, B.T.; Houten, S.M.; et al. Liver disease predominates in a mouse model for mild human Zellweger spectrum disorder. *Biochim. et Biophys. Acta (BBA) Mol. Basis Dis.* 2019, 1865, 2774–2787. [CrossRef]

30. Berendse, K.; Koot, B.G.P.; Klouwer, F.C.C.; Engelen, M.; Roels, F.; Lacle, M.M.; Nikkels, P.G.J.; Verheij, J.; Poll-The, B.T. Hepatic symptoms and histology in 13 patients with a Zellweger spectrum disorder. *J. Inherit. Metab. Dis.* 2019, 42, 955–965. [CrossRef]

31. Wang, L.-J.; Wang, L.; Chen, Y.M.; George, D.; Smets, F.; Sokal, E.M.; Bremer, E.G.; Soriano, H.E. Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences. *Liver Transplant.* 2002, 8, 822–828. [CrossRef]

32. Gupta, S.; Rajvanshi, P.; Sokhi, R.; Slepia, S.; Yam, A.; Kerr, A.; Novikoff, P.M. Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium. *Hepatology* 1999, 29, 509–519. [CrossRef] [PubMed]

33. Ferdinandusse, S.; Denis, S.; Faust, P.L.; Wanders, R.J.A. Bile acids: The role of peroxisomes. *J. Lipid Res.* 2009, 50, 2139–2147. [CrossRef] [PubMed]

34. Olszewski, W.L.; Poreda, E.; Jaskowska-Englisz, M.; Interewicz, B. Hepatocyte transplantation–granulocytes and mononuclear cells recognize the surface of isolated autologous hepatocytes as non-self and destroy them. *Transpl. Int.* 1998, 11, 367.

35. Joseph, B.; Malhi, H.; Bhargava, K.K.; Palestro, C.J.; McCuskey, R.S.; Gupta, S. Kupffer cells participate in early clearance of syngeneic hepatocytes transplanted in the rat liver. *Gastroenterology* 2002, 123, 1677–1685. [CrossRef] [PubMed]

36. Gustafson, E.; Elgue, G.; Hughes, R.D.; Mitry, R.R.; Sanchez, J.; Haglund, U.; Meurling, S.; Dhawan, A.; Korsgren, O.; Nilsson, B. The Instant Blood-Mediated Inflammatory Reaction Characterized in Hepatocyte Transplantation. *Transplantation* 2011, 91, 632–638. [CrossRef] [PubMed]

37. Coppin, L.; Sokal, E.; Stéphenne, X. Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives. *Cells* 2019, 8, 1160. [CrossRef]

38. Rajvanshi, P.; Kerr, A.; Bhargava, K.K.; Burk, R.D.; Gupta, S. Studies of liver repopulation using the dipeptidyl peptide IV-deficient rat and other rodent recipients: Cell size and structure relationships regulate capacity for increased transplanted hepatocyte mass in the liver lobule. *Hepatology* 1996, 23, 482–496. [CrossRef]

39. Gupta, S.; Rajvanshi, P.; Lee, C.D. Integration of transplanted hepatocytes into host liver plates demonstrated with dipeptidyl peptidase IV-deficient rats. *Proc. Natl. Acad. Sci. USA* 1995, 92, 5860–5864. [CrossRef]

40. Berendse, K.; Engelen, M.; Ferdinandusse, S.; Majoie, C.B.I.M.; Waterham, H.R.; Vaz, F.M.; Koelman, J.H.T.M.; Barth, P.G.; Wanders, R.J.A.; Poll-The, B.T. Zellweger spectrum disorders: Clinical manifestations in patients surviving into adulthood. *J. Inherit. Metab. Dis.* 2016, 39, 93–106. [CrossRef]

41. Dollet, P.-E.; Ravaud, J.; André, F.; Najimi, M.; Sokal, E.; Lombard, C. Comprehensive Screening of Cell Surface Markers Expressed by Adult-Derived Human Liver Stem/Progenitor Cells Harvested at Passage 5: Potential Implications for Engraftment. *Stem Cells Int.* 2016, 2016, 1–12. [CrossRef]
42. Yamanouchi, K.; Zhou, H.; Platt, J.L.; Fox, I.J.; Roy-Chowdhury, J.; Guha, C.; Roy-Chowdhury, N.; Macaluso, F.; Liu, L.; Yamamoto, T.; et al. Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. *Hepatology* 2008, 49, 258–267. [CrossRef] [PubMed]

43. Gaillard, M.; Tranchart, H.; Lainas, P.; Trassard, O.; Remy, S.; Dubart-Kupperschmitt, A.; Dagher, I. Improving Hepatocyte Engraftment Following Hepatocyte Transplantation Using Repeated Reversible Portal Vein Embolization in Rats. *Liver Transplant.* 2019, 25, 98–110. [CrossRef] [PubMed]

44. Najimi, M.; Khuu, D.N.; Lysy, P.A.; Jazouli, N.; Abarca-Quinones, J.; Sempoux, C.; Sokal, E.M. Adult-Derived Human Liver Mesenchymal-Like Cells as a Potential Progenitor Reservoir of Hepatocytes? *Cell Transplant.* 2007, 16, 717–728. [CrossRef] [PubMed]

45. Barahman, M.; Asp, P.; Roy-Chowdhury, N.; Kinkhabwala, M.; Roy-Chowdhury, J.; Kabarriti, R.; Guha, C. Hepatocyte Transplantation: Quo Vadis? *Int. J. Radiat. Oncol.* 2019, 103, 922–934. [CrossRef]